ImmunityBio announced that it has named Enrique Dilone to the newly created role of chief technology officer. With more than three decades of pharmaceutical manufacturing expertise, Dilone will assume responsibility for all global manufacturing functions as the company prepares for potential FDA approval of a key bladder cancer drug. He will report directly to president and CEO Richard Adcock. Prior to joining ImmunityBio, Dilone served as Chief Technology Officer of Prothelia.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IBRX: